Akèy › Skleroz Miltip › Kalifòni
Etid klinik pou Skleroz Miltip nan Kalifòni
24 etid pou Skleroz Miltip ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Fresno
- TG Therapeutics Investigational Trial Site, Newport Beach
- TG Therapeutics Investigational Trial Site, Orange
- ak 1 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06433752Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
- UC San Diego, La Jolla
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT07477639RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Kadima Neuropsychiatry Institute, San Diego
- Providence Medical Foundation, Santa Rosa
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Private Practice - Dr. Regina Berkovich- Site Number : 8400005, West Hollywood
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 15, 2026 · NCT07325292Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Local Institution - 0114, Loma Linda
- University of California Davis Health, Sacramento
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Sep 10, 2026 · NCT06408259A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, La Jolla
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford Neuroscience Health Center, Palo Alto
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 14, 2026 · NCT07304154Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- University of California-San Francisco, San Francisco
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 64 · Fanm · Mizajou Aug 11, 2026 · NCT06940323A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Fullerton Neuro and Headache Ctr, Fullerton
- Regina Berkovich MD PhD Inc, West Hollywood
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07225504Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
- Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco
Ap rekriteFaz 1/2
Laj 18 a 55 · Tout sèks · Mizajou Jul 2, 2026 · NCT05359653Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
- Byers Hall, San Francisco
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT07510607Care in Multiple Sclerosis (MS)
- University of California, San Francisco, San Francisco
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT07011914ECoG BMI for Motor and Speech Control
- University of California San Francisco, San Francisco
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT03698149Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
- Stanford University, Redwood City
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Mar 23, 2026 · NCT07139743Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- University of California San Francisco, San Francisco
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Mar 11, 2026 · NCT02521311A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Stanford Multiple Sclerosis Center, Palo Alto
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Feb 27, 2026 · NCT06138132Central Vein Sign in Multiple Sclerosis Extension Study
- Cedars-Sinai Medical Center, Los Angeles
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Feb 20, 2026 · NCT07424027"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- University of California, San Francisco, San Francisco
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 31, 2025 · NCT07222618Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
- UCSF, San Francisco
- Stanford University, Stanford
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 80 · Tout sèks · Mizajou May 2, 2025 · NCT05395624Kesimpta (Ofatumumab) Pregnancy Registry
- University of California San Diego OTIS, La Jolla
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Jan 14, 2025 · NCT05634967Entire-body PET Scans for Multiple Sclerosis
- Brain Health Alliance, Ladera Ranch
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 25 a 55 · Tout sèks · Mizajou Jan 7, 2025 · NCT04390009Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- Novartis Investigative Site, La Jolla
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Fanm · Mizajou May 16, 2024 · NCT04933552MS-ResearchBiomarkerS
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteEtid obsèvasyonVolontè an sante akeyiMande peman pou patisipan yo
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2024 · NCT05204459Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.